Global Subdermal Contraceptive Implants Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Subdermal Contraceptive Implants Market is presumed to reach the market size of nearly USD 1213.87 Million by 2032 from USD 829.59 Million in 2023 with a CAGR of 4.32% under the study period 2024-2032.

Subdermal contraceptive implants imply delivery of a steroid progestin from polymer capsules or rods surgically implanted into the upper non-dominant arm. Typically, the protection span is 1-5 years, however, it varies based on the type of progestin and polymer used. Once the implant is inserted, it allows a woman to have coitus for certain time without any substantial risk of getting pregnant. The implants are of a size of matchstick and works by constraining ovulation. The progestin thickens the cervical mucus, which then restricts the passage of sperm to the uterus. The progestin is responsible for thinning the endometrium which then inhibits implantation.

MARKET DYNAMICS

With more people embracing modern and safe contraceptive methods, an increase in disposable income and population control advisory issued by the government is steering the growth of the worldwide subdermal contraceptive implant market. However, issues like psychological side-effects, chances of failure and a well-established market of contraceptive pills are expected to hamper the market growth. The subdermal contraceptive implants are expected to witness huge demands owing to its efficacy, longer span of contraception, and easy insertion and removal procedure. Other factors driving the global revenues of the subdermal contraceptive market are the rising number of working women, unplanned pregnancies and rising concern regarding sexual health.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Subdermal Contraceptive Implants. The growth and trends of Subdermal Contraceptive Implants industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Subdermal Contraceptive Implants market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Etonogestrel Implant
Levonorgestrel Implant
Others

By Application

Hospital
Clinic
Research Facilities

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Subdermal Contraceptive Implants market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Subdermal Contraceptive Implants market include Merck & Co. Inc., Shanghai Dahua Pharmaceutical Co. Ltd, Bayer AG, Wyeth Pharmaceuticals, Baxter, BD, Gerresheimer AG, Pfizer Inc., Novartis AG, Schott AG, Eli Lilly And Company, Sandoz International GmbH, Terumo Corporation, Teva Pharmaceutical Industries Ltd., West Pharmaceutical Services Inc., SHL Medical AG, Insulet Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11211804

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. SUBDERMAL CONTRACEPTIVE IMPLANTS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL SUBDERMAL CONTRACEPTIVE IMPLANTS MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data
5.3. Analysis By Type
5.4. Etonogestrel Implant Historic and Forecast Sales By Regions
5.5. Levonorgestrel Implant Historic and Forecast Sales By Regions
5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL SUBDERMAL CONTRACEPTIVE IMPLANTS MARKET ANALYSIS BY APPLICATION

6.1. Overview By Application
6.2. Historical and Forecast Data
6.3. Analysis By Application
6.4. Hospital Historic and Forecast Sales By Regions
6.5. Clinic Historic and Forecast Sales By Regions
6.6. Research Facilities Historic and Forecast Sales By Regions

7. GLOBAL SUBDERMAL CONTRACEPTIVE IMPLANTS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE SUBDERMAL CONTRACEPTIVE IMPLANTS COMPANIES

8.1. Subdermal Contraceptive Implants Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF SUBDERMAL CONTRACEPTIVE IMPLANTS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Merck & Co. Inc.
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Shanghai Dahua Pharmaceutical Co. Ltd
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Bayer AG
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Wyeth Pharmaceuticals
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Baxter
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. BD
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Gerresheimer AG
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Pfizer Inc.
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Novartis AG
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Schott AG
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments
9.13. Eli Lilly And Company
- 9.13.1 Company Overview
- 9.13.2 Company Revenue
- 9.13.3 Products
- 9.13.4 Recent Developments
9.14. Sandoz International GmbH
- 9.14.1 Company Overview
- 9.14.2 Company Revenue
- 9.14.3 Products
- 9.14.4 Recent Developments
9.15. Terumo Corporation
- 9.15.1 Company Overview
- 9.15.2 Company Revenue
- 9.15.3 Products
- 9.15.4 Recent Developments
9.16. Teva Pharmaceutical Industries Ltd.
- 9.16.1 Company Overview
- 9.16.2 Company Revenue
- 9.16.3 Products
- 9.16.4 Recent Developments
9.17. West Pharmaceutical Services Inc.
- 9.17.1 Company Overview
- 9.17.2 Company Revenue
- 9.17.3 Products
- 9.17.4 Recent Developments
9.18. SHL Medical AG
- 9.18.1 Company Overview
- 9.18.2 Company Revenue
- 9.18.3 Products
- 9.18.4 Recent Developments
9.19. Insulet Corporation
- 9.19.1 Company Overview
- 9.19.2 Company Revenue
- 9.19.3 Products
- 9.19.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies